RecruitingNCT06755775
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Sponsor
Ruijin Hospital
Enrollment
150 participants
Start Date
Jul 23, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Pathologic diagnosis of DLBCL
- Patient's general condition is good and survival is expected to be greater than six months
- Signed and dated informed consent form
Exclusion Criteria4
- Combined with other malignant tumors
- Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
- Pregnant women and women at risk of pregnancy, breastfeeding women
- poor compliant
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06755775
Related Trials
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT0459464227 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT060263191 location
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347246 locations
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686174 locations